Telix Pharmaceut SEC Filings

Telix Pharmaceuticals Ltd director Marie Elizabeth McDonald has filed an initial ownership report on Form 3. The filing shows an indirect holding of 3,719 Ordinary Shares held through Netwealth Investments Limited as custodian. This is a disclosure of existing holdings rather than a new share purchase or sale.

Telix Pharmaceuticals Ltd director Jann Elizabeth Skinner has filed an initial ownership report showing a significant indirect stake in the company. The Form 3 discloses indirect ownership of 595,000 Ordinary Shares held through Forellan Pty Limited, where Ms. Skinner is the sole director and shareholder. This filing records her existing position rather than new share purchases or sales.

Telix Pharmaceuticals Ltd director Jann Elizabeth Skinner has filed an initial ownership report showing a significant indirect stake in the company. The Form 3 discloses indirect ownership of 595,000 Ordinary Shares held through Forellan Pty Limited, where Ms. Skinner is the sole director and shareholder. This filing records her existing position rather than new share purchases or sales.

Telix Pharmaceuticals Ltd managing director and Group CEO Christian Behrenbruch has filed an initial statement of holdings, detailing his equity and derivative interests in the company. He holds performance share appreciation rights over 93,114 ordinary shares at an exercise price of 4.9500 (Australian dollars) expiring on April 4, 2027, and further rights over 100,223 ordinary shares at 6.9000 expiring on December 31, 2027. These PSARs were granted in April 2022 and May 2023 and are already vested and exercisable.

Behrenbruch also holds share rights over 2,595 ordinary shares at a zero exercise price, expiring on March 31, 2028, which are likewise vested and exercisable. Indirectly, 20,675,000 ordinary shares are held through Elk River Holdings Pty Ltd, where he is the sole director and shareholder. In addition, he directly owns 400,000 American Depositary Receipts, each convertible into one ordinary share with no expiration date, and 254,006 ordinary shares held directly.

Telix Pharmaceuticals Ltd managing director and Group CEO Christian Behrenbruch has filed an initial statement of holdings, detailing his equity and derivative interests in the company. He holds performance share appreciation rights over 93,114 ordinary shares at an exercise price of 4.9500 (Australian dollars) expiring on April 4, 2027, and further rights over 100,223 ordinary shares at 6.9000 expiring on December 31, 2027. These PSARs were granted in April 2022 and May 2023 and are already vested and exercisable.

Behrenbruch also holds share rights over 2,595 ordinary shares at a zero exercise price, expiring on March 31, 2028, which are likewise vested and exercisable. Indirectly, 20,675,000 ordinary shares are held through Elk River Holdings Pty Ltd, where he is the sole director and shareholder. In addition, he directly owns 400,000 American Depositary Receipts, each convertible into one ordinary share with no expiration date, and 254,006 ordinary shares held directly.

Telix Pharmaceuticals Limited has resubmitted a New Drug Application to the U.S. FDA for TLX101-Px (Pixclara), a PET imaging agent designed to help distinguish recurrent or progressive glioma from treatment-related brain changes in adult and pediatric patients.

The resubmission includes additional data and statistical analyses requested in a prior Complete Response Letter, alongside the original primary data set. TLX101-Px has Orphan Drug and Fast Track designations, reflecting its potential to address a significant unmet need, as there is currently no FDA-approved targeted amino acid PET agent for adult and pediatric brain cancer imaging in the U.S.

Telix Pharmaceuticals Limited has resubmitted a New Drug Application to the U.S. FDA for TLX101-Px (Pixclara), a PET imaging agent designed to help distinguish recurrent or progressive glioma from treatment-related brain changes in adult and pediatric patients.

The resubmission includes additional data and statistical analyses requested in a prior Complete Response Letter, alongside the original primary data set. TLX101-Px has Orphan Drug and Fast Track designations, reflecting its potential to address a significant unmet need, as there is currently no FDA-approved targeted amino acid PET agent for adult and pediatric brain cancer imaging in the U.S.

Telix Pharmaceuticals reported that Part 1 of its ProstACT Global Phase 3 study for TLX591-Tx in metastatic castration resistant prostate cancer achieved its primary objectives, showing an acceptable safety and tolerability profile with no new safety signals in 36 treated patients.

Patients received two doses of TLX591-Tx 14 days apart alongside standard therapies (enzalutamide, abiraterone or docetaxel) across three cohorts of 11, 11 and 14 patients. Most non-hematologic side effects were low grade, hematologic events were transient and manageable, and organ radiation exposure was below established safety limits. The study has already advanced into Part 2 outside the U.S., and Telix plans to present Part 1 data to the FDA to seek an IND amendment to expand Part 2 in the U.S.

Telix Pharmaceuticals files its annual report detailing a growing commercial radiopharmaceutical business alongside continued losses and regulatory risk. The company reported a loss after tax of $7.1 million and net operating cash outflow of $17.3 million for the year, with an accumulated deficit of $154.5 million. As of December 31, 2025, Telix held $141.9 million in cash and cash equivalents and had $426.1 million of 2.375% unsecured convertible bonds due 2029, plus $10.3 million of other debt, against 338,777,049 ordinary shares outstanding.

The business now relies heavily on two approved imaging products, Illuccix and Gozellix, which are commercial in multiple jurisdictions. However, key pipeline programs have faced regulatory setbacks: TLX250‑Px and TLX101‑Px each received FDA Complete Response Letters requiring additional chemistry, manufacturing, controls and clinical evidence, and both are being prepared for resubmission. The Phase 3 ProstACT Global trial of therapeutic candidate TLX591‑Tx is underway. Management highlights the need for potential additional capital, execution of its acquisition integrations, and careful control of leverage while advancing an expanding clinical and commercial footprint.

Telix Pharmaceuticals Limited reports strong 2025 growth but lower profitability. Revenue rose to US$803.8 million, a 56% increase from 2024, driven by its Precision Medicine business and the RLS Radiopharmacies acquisition. Operating profit was US$29.8 million, yet higher R&D, manufacturing scale-up, and finance costs led to a net loss after tax of US$7.1 million, versus a US$33.7 million profit a year earlier.

Adjusted EBITDA declined to US$39.5 million as Telix increased R&D spending to US$171.2 million and expanded manufacturing infrastructure in the U.S., Europe, Japan, and Australia. Cash and equivalents fell to US$141.9 million from US$440.0 million, reflecting acquisition payments and capital investment, while the company continued advancing late-stage therapeutic trials and global product launches.

Telix Pharmaceuticals Limited reports strong 2025 growth but lower profitability. Revenue rose to US$803.8 million, a 56% increase from 2024, driven by its Precision Medicine business and the RLS Radiopharmacies acquisition. Operating profit was US$29.8 million, yet higher R&D, manufacturing scale-up, and finance costs led to a net loss after tax of US$7.1 million, versus a US$33.7 million profit a year earlier.

Adjusted EBITDA declined to US$39.5 million as Telix increased R&D spending to US$171.2 million and expanded manufacturing infrastructure in the U.S., Europe, Japan, and Australia. Cash and equivalents fell to US$141.9 million from US$440.0 million, reflecting acquisition payments and capital investment, while the company continued advancing late-stage therapeutic trials and global product launches.

Telix Pharmaceuticals Limited submitted a European Marketing Authorization Application for its product candidate TLX101-Px, which is designed for brain cancer imaging. The company reported this regulatory milestone to U.S. investors by furnishing on Form 6-K the related announcement it filed with the Australian Securities Exchange.

Telix Pharmaceuticals Limited submitted a European Marketing Authorization Application for its product candidate TLX101-Px, which is designed for brain cancer imaging. The company reported this regulatory milestone to U.S. investors by furnishing on Form 6-K the related announcement it filed with the Australian Securities Exchange.

Telix Pharmaceuticals Limited has announced a leadership change at the Board level. Ms. Tiffany Olson has resigned as Non-Executive Director and Board Chair, effective 3 February 2026.

Long-standing independent Non-Executive Director Dr. Mark Nelson has been appointed Interim Chair. The Board states it is in advanced stages of appointing new Non-Executive Directors and is committed to naming a new Independent Chair as soon as feasible. Dr. Nelson emphasized appreciation for Olson’s service and reiterated that Telix has a strong commercial business and pipeline, and that this governance change is not expected to affect delivery of near-term milestones or the company’s long-term growth strategy.

Telix Pharmaceuticals Limited filed a Form 6-K highlighting two key updates first released on the Australian Securities Exchange. The company reports that the Chinese National Medical Products Administration has accepted a New Drug Application for Illucix, marking an important regulatory step for this product in China. Telix also states that it achieved its FY 2025 guidance with US$804 million (A$1.2 billion) in revenue and is accelerating growth with the launch of Gozellix. Together, these disclosures point to strong recent commercial performance and progress in expanding the company’s product portfolio and geographic reach.

Telix Pharmaceuticals Limited filed a Form 6-K highlighting two key updates first released on the Australian Securities Exchange. The company reports that the Chinese National Medical Products Administration has accepted a New Drug Application for Illucix, marking an important regulatory step for this product in China. Telix also states that it achieved its FY 2025 guidance with US$804 million (A$1.2 billion) in revenue and is accelerating growth with the launch of Gozellix. Together, these disclosures point to strong recent commercial performance and progress in expanding the company’s product portfolio and geographic reach.